
Vasamed Inc. Stock Analysis VSMD
Väsamed, Inc. engages in the design, licensing, manufacture, and distribution of a range of non-invasive hemodynamic technologies for vascular, wound care, cardiovascular and emergency medicine diagnostics. The company is headquartered in Minneapolis, Minnesota. Its SensiLase peripheral arterial disease (PAD)-IQ Studycast System provides measurement of tissue perfusion of the extremities particularly in patients with combined peripheral arterial disease and diabetes. The SensiLase PAD-IQ Studycast supports non-invasive upper and lower extremity vascular assessments, including skin perfusion pressure microcirculation pulse volume recording and ankle brachial index (ABI) calculation for doppler-obtained pressures; data sorting and customization options to support database mining, and wound imaging and surface area calculation featuring SmartDraw. SensiLase PAD-IQ System featuring Studycast Data Management offers health professionals various support tools for both PAD and critical limb ischemia. Its AcQtrac System technology is designed to measure cardiac and hemodynamic parameters.
Read More Vasamed Inc (VSMD) Chart
Key Statistics of Vasamed Inc (VSMD)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$0.00Volume
-P/E Ratio (TTM)
-Market Cap
8.00Avg. Volume
-Dividend Yield
-Financial Metrics & Statements of Vasamed Inc (VSMD)
FAQ's for Vasamed Inc (VSMD)
- According to Musaffa’s Shariah screening methodology, Vasamed Inc (VSMD) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.